Prediction of Incident Diabetic Neuropathy Using the Monofilament Examination

A 4-year prospective study

OBJECTIVE — To determine the specific monofilament examination score that predicts the subsequent 4-year incidence of diabetic neuropathy with the highest degree of diagnostic accuracy.

RESEARCH DESIGN AND METHODS — Longitudinal follow-up of 175 of 197 (89%) participants in the Toronto Diabetic Neuropathy Cohort without baseline neuropathy for incident neuropathy. We examined the baseline monofilament examination score (and other simple sensory screening tests) by receiver operating characteristic (ROC) curve analysis.

RESULTS — Incident diabetic neuropathy developed in 50 (29%) participants over a mean follow-up of 4.1 years (interquartile range 2.6–7.1 years). Although male sex, longer diabetes duration, taller height, and higher blood pressure at baseline were associated with incident neuropathy, the strongest association was with a lower baseline monofilament score (score of 8 was 3.7 ± 2.5 for incident neuropathy vs. 5.7 ± 2.3 for those who did not develop neuropathy; P < 0.001). The optimal threshold score for risk of incident neuropathy was ≤5 sensate stimuli out of 8, with 72% sensitivity, 64% specificity, positive and negative likelihood ratios of 2.5 and 0.35, and positive and negative predictive values of 87 and 46%, respectively (χ² = 20.7, P < 0.001). Area under the ROC curve was significantly greater for the monofilament examination compared with that for other simple sensory tests.

CONCLUSIONS — A simple threshold of ≤5 sensate stimuli out of 8 discriminates 4-year risk of diabetic neuropathy with acceptable operating characteristics. Although there are limitations in its specificity for prediction of future neuropathy onset, the monofilament examination is appropriate as a simple diabetic neuropathy screening instrument generalizable to the clinical setting.

From the 1Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; and the 2Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Corresponding author: Bruce A. Perkins, bruce.perkins@uhn.on.ca.

Received 2 October 2009 and accepted 20 March 2010. Published ahead of print at http://care.diabetesjournals.org on 31 March 2010. DOI: 10.2337/dc09-1835.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
neuropathy for the future onset of diabetic neuropathy through the Toronto Diabetic Neuropathy Cohort (10,12). To our knowledge, it represents the only prospective observational study designed to assess the predictive validity (the validity in identifying future risk of neuropathy onset) of a simple screening test for diabetic neuropathy.

**RESEARCH DESIGN AND METHODS** — Subjects without diabetic neuropathy in the first cross-sectional examination of the Toronto Diabetic Neuropathy Cohort were eligible for the current study (10,12). The protocol and consent procedures were approved by the Multidisciplinary Research Ethics Board of the Toronto General Hospital Research Institute.

From 1999 and 2001, 478 subjects were examined as part of the Toronto Diabetic Neuropathy Cohort, a cross-sectional study investigating the concurrent validity of screening tests (10,12). A clinical stratification method based on the Toronto Clinical Neurathy Score was used in the accrual of this cohort to ensure that it would consist of subjects with a broad spectrum of nerve injury (10,14). Four severity strata, including no neuropathy, mild neuropathy, moderate neuropathy, and severe neuropathy, were graded according to the score quartiles, and accrual of subjects into the study was terminated only when the smallest stratum contained 50 subjects. A comprehensive evaluation was also conducted to exclude risk of neuropathy from other etiologies such as familial, alcoholic, nutritional, and uremic polyneuropathy. The 51 nondiabetic reference subjects in the total cohort of 478 were excluded from the current analysis. Of the remaining 427 subjects with diabetes (65 type 1 and 362 type 2 diabetes), 197 did not meet the diagnostic criteria for diabetic neuropathy and were thus eligible for study. We were able to reevaluate 175 of the 197 subjects (89%) from 2004 until 2007 using the same clinical and electrophysiological examination to identify incident cases of diabetic neuropathy.

**Determination of the monofilament score and other sensory screening test scores**

The monofilament examination was performed bilaterally using a 10-g (size 5.07) monofilament according to previous study (10,12). In brief, first a reference stimulus was applied to the forehead or the sternum. With the patient’s eyes closed, the monofilament was applied to a noncalloused site on the dorsum of the great toe just proximal to the nail bed using a smooth motion: the skin was touched and the monofilament was bent for a full second and then lifted from the skin. This maneuver was repeated 4 times per foot in a random arrhythmic manner. The responses were tallied to produce a score ranging from 0 to 8 (normal [1 point assigned], decreased [0.5 point assigned], or absent [0 points assigned]) A score of 0 represented a complete lack of perception, whereas a score of 8 represented full perception of all stimuli. Inter- and intrarater reproducibility was very good to excellent for the performance of the monofilament examination according to this protocol (10). Superficial pain sensation was measured using a sterile Neuropit (Owen Mumford, Oxford, U.K.) applied four times to the same sites, and the score (from 0 to 8) was defined as the total number of times the application of the pain sensation was perceived. Vibration testing by the on-off method was conducted using a 128-Hz tuning fork applied to the bony prominence at the dorsum of the first toe just proximal to the nail bed. The patient reported perception of both the start of the vibration sensation and the cessation on dampening, conducted twice on each toe, and the score (between 0 and 8) was defined as the total number of times application and dampening were felt. Vibration testing by the timed method was measured by the patient reporting the time at which vibration diminished beyond perception. The tuning fork was then applied to the dorsal aspect of the distal phalanx of the examiner’s thumb. The time (in seconds) at which vibration sensation diminished beyond the examiner’s perception was then added from both sides to provide a single score. Vibration perception threshold (VPT) testing was measured quantitatively by the method of limits using the Medoc device (Medoc Advanced Medical Systems, Durham, NC). Each test was performed by an examiner blinded to results of all other examinations.

**Determination of incident diabetic neuropathy: the reference standard**

Incident diabetic neuropathy was defined by clinical and electrophysiological criteria according to the consensus of the American Association of Neurology, the American Academy of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation (15). Based on this consensus, incident case definition generally required the presence of electrophysiological polyneuropathy as defined by abnormality of three or more parameters in two or more nerves in combination with the presence of more than one neuropathic symptom or sign of peripheral neuropathy. This same criterion was used to both exclude the presence of diabetic neuropathy at baseline and to define incident neuropathy during follow-up.

For the electrophysiological component of incident case definition, evaluation of the unilateral median, ulnar, peroneal, tibial, and sural nerves was performed at baseline and subsequent examinations were performed using standardized nerve conduction studies (16). These were performed using the Counterpoint instrument (Natus Medical, San Carlos, CA) according to the standards of the American Association for Neuromuscular and Electrodiagnostic Medicine and the Canadian Society of Clinical Neurophysiology. Low interobserver and intraobserver variabilities have been observed for these measurements using the techniques described (17). Individual nerve conduction parameters were scored as normal or abnormal according to laboratory reference values.

**Statistical analysis**

Analyses were performed in SAS (version 9.1 for Windows). Using the methods for power calculation in the ROC analysis of Hanley and McNeil (18), given a type 1 error ($\alpha$ level) of 0.05, we anticipated 94.5% power to discriminate an area under the curve from the null hypothesis in which the diagnostic accuracy is no different from chance alone (area under the curve [AUC] = 0.5) under the assumption that incident diabetic neuropathy would occur in approximately one-third of diabetic individuals. Differences in baseline characteristics between individuals with incident cases of diabetic neuropathy and control subjects were assessed using $\chi^2$ tests for categorical variables. For these differences in baseline characteristics, continuous variables were compared using the two-sided Mann-Whitney $U$ test (Wilcoxon rank-sum test) because some variables (height, in meters) were not normally distributed. Significance was based on an $\alpha$ level of 0.05. We also pursued a multivariate logistic regression model to determine clin-
commonly used agents were ramipril, enalapril, and lisinopril, respectively.‡ By subject self-report.

values for the two-sided Mann-Whitney

of the threshold determined from ROC
defined by the threshold equal to or be-

positive monofilament score result was

rocopathy, a receiver operating characteris-
tic (ROC) curve was generated (19). The

of 4-year incident diabetic neuropathy.

Table 1—Baseline characteristics of the 175 subjects according to the 4-year incident diabetic neuropathy

| Characteristic                   | Incident diabetic neuropathy | Absent | Present | P value* |
|----------------------------------|-----------------------------|--------|---------|----------|
| n                                |                             | 125    | 50      |          |
| Age at baseline (years)          |                             | 56 ± 8 | 57 ± 8  | 0.08     |
| Male sex (%)                     |                             | 78 (62)| 40 (80) | 0.03     |
| Type 2 diabetes (%)              |                             | 106 (85)| 41 (82) | 0.65     |
| Diabetes duration (years)        |                             | 11 ± 9 | 15 ± 9  | 0.02     |
| Current/past smoking (%)         |                             | 68 (54)| 28 (56) | 0.65     |
| Alcohol consumption ≥3 equivalents/day |                     | 17 (14) | 7 (14)  | 0.96     |
| Diabetes therapy                 |                             |        |         |          |
| Insulin use                      |                             | 50 (40)| 24 (48) | 0.38     |
| Oral hypoglycemic agent use      |                             | 63 (55)| 26 (52) | 0.38     |
| ACE inhibitor agents†            |                             | 28 (22)| 18 (36) | 0.14     |
| Retinopathy history‡             |                             | 18 (14)| 11 (22) | 0.19     |
| Nephropathy history‡             |                             | 8 (16) | 9 (18)  | 0.89     |
| Foot ulcer history‡              |                             | 6 (5)  | 3 (6)   | 0.88     |
| Height (m)                       |                             | 1.69 ± 0.09 | 1.73 ± 0.07 | 0.10     |
| Weight (kg)                      |                             | 82.8 ± 14.6 | 86.5 ± 16.5 | 0.73     |
| BMI (kg/m²)                      |                             | 29.0 ± 4.7 | 29.0 ± 5.1 | 0.57     |
| Systolic blood pressure (mmHg)   |                             | 132 ± 15 | 139 ± 14 | 0.04     |
| Diastolic blood pressure (mmHg)  |                             | 82 ± 8  | 86 ± 8  | 0.05     |
| A1C (%)                          |                             | 8.2 ± 1.5 | 8.6 ± 1.3 | 0.22     |
| Monofilament score               |                             |        |         | <0.001   |
| Mean ± SD                        |                             | 5.7 ± 2.3 | 3.7 ± 2.5 |          |
| Interquartile range              |                             | 4.0–8.0 | 1.5–5.5 |          |
| Other screening test scores      |                             |        |         |          |
| Vibration by the on-off method   |                             | 6.5 ± 2.4 | 5.5 ± 3.0 | 0.03     |
| (score 0–8)                      |                             |        |         |          |
| Vibration by the timed method    |                             | 28 ± 13 | 34 ± 14 | 0.02     |
| (in seconds)                     |                             |        |         |          |
| Superficial pain score           |                             | 6.5 ± 2.2 | 5.5 ± 3.0 | 0.04     |
| (score 0–8)                      |                             |        |         |          |
| VPT (µm)                         |                             | 21.9 ± 14.8 | 30.5 ± 15.3 | <0.001   |

Data are means ± SD or n (%) unless otherwise indicated. *Categorical variables report P values for χ² test statistics. Although continuous variables were generally distributed except for height, we report P values for the two-sided Mann-Whitney U test (Wilcoxon rank-sum test). †ACE inhibitor agents. The most commonly used agents were ramipril, enalapril, and lisinopril, respectively. ‡By subject self-report.

Results

The 175 subjects were examined for a second examination at a mean of 4.1 years after baseline examination. This distribution was skewed to the right with an interquartile range of 2.6 to 7.1 years. Among those with incident DSP, the median follow-up was 3.9 years (interquartile range 2.5–7.1 years), whereas for those without incident DSP it was 4.3 (interquartile range 2.5–7.1 years), with a Wilcoxon rank-sum two-sided test P value of 0.35. The clinical characteristics of the 22 eligible subjects who were unable to reexamine did not differ from those of subjects who were examined. Incident diabetic neuropathy developed in 50 (29%) of the 175 subjects. In none of the subjects was polyneuropathy owing to nondiabetic causes recognized.

The characteristics of the 175 study subjects at the time of baseline evaluation are summarized in Table 1, according to the absence or presence of incident diabetic neuropathy at the final examination. Incident diabetic neuropathy occurred more frequently in male subjects. Although no age differences were seen, case subjects had significantly longer diabetes duration. No differences in diabetes type, smoking, or alcohol consumption were observed at baseline between subjects with incident cases and their control subjects. Height, weight, and BMI were similar between case and control subjects, yet both systolic and diastolic blood pressure values were significantly higher in subjects with incident cases of diabetic neuropathy. Differences between subjects with incident cases and control subjects without onset of neuropathy were observed for the baseline monofilament score and the VPT values. To further explore these observations, we pursued a multivariate model that included all of the variables listed in the table, including those likely to be collinear (the simple screening tests and VPT testing scores). A lower baseline monofilament score was the only variable independently associated with neuropathy incidence (χ² 10.5; P = 0.0012). By using the median value of the score to determine odds ratios for risk, the adjusted odds ratio for incident diabetic neuropathy associated with a monofilament score >5 compared with ≤5 was 5.5 (95% CI 1.9–15.9). Although demonstrating a trend toward higher values among subjects with incident cases of diabetic neuropathy, the baseline A1C values were not significantly different either in the univariate or adjusted comparisons. The duration of time between baseline and follow-up examinations did not differ between case and control subjects.

In view of the strong odds ratio observed for the monofilament score, we pursued ROC curve analysis to determine the optimal threshold score for prediction of 4-year incident diabetic neuropathy.
The result of the ROC analysis for the monofilament score is represented by the solid black line in Fig. 1. The combination of an optimal sensitivity of 72% and optimal specificity of 64% was observed at a cutoff level for positivity of ≤5 correct responses out of 8. This threshold was associated with very good sensitivity (72%) and negative predictive value (87%), implying that the finding of a negative test result, a monofilament score >5 correct responses out of 8, implies the lowest 4-year risk for the onset of neuropathy. This sensitivity highlights the major advantage of the monofilament examination in clinical practice, which is to rule out subsequent risk of disease in those without neuropathy. However, this advantage is limited by a lower specificity and positive predictive value (65 and 46%, respectively), indicating that the monofilament score cannot confidently rule in risk of disease. Rather, the monofilament score can be used to rule out such risk, which ultimately is the necessary characteristic of a routine screening test.

Of critical importance in the clinical care of patients with diabetes is the process of risk stratification for diabetes complications at a preclinical stage when injury is absent or incipient and when clinical interventions are most likely to be effective for prevention of progression to advanced injury. For example, urinary albumin excretion is a quantitative variable for which a specific range of values, termed microalbuminuria, has become firmly entrenched in clinical practice as it is seen as a marker of incipient renal injury in diabetes (21). Identification of microalbuminuria permits interventions that are designed to prevent progression to advanced kidney disease, years before its development. Conversely, identification

**Table 2—Comparison of area under the ROC curve between the monofilament score and the other screening test scores**

| Test                  | Area under the ROC curve | P value* | Mean AUC (95% distribution) | P value† |
|-----------------------|--------------------------|----------|-----------------------------|----------|
| Monofilament          | 0.71                     | —        | 0.71 (0.62, 0.80)           | —        |
| Other simple tests    |                          |          |                             |          |
| Vibration by the on-off method | 0.59                | 0.007    | 0.59 (0.50, 0.67)           | <0.0001  |
| Vibration by the timed method | 0.61                |          | 0.61 (0.52, 0.70)           | <0.0001  |
| Superficial pain score | 0.57                    | <0.0001  | 0.57 (0.48, 0.66)           | <0.0001  |
| Quantitative tests    |                          |          |                             |          |
| VPT                   | 0.67                     | 0.094    | 0.67 (0.59, 0.76)           | <0.0001  |

*P value for comparison with the AUC for the monofilament score, according to the method of Pencina et al. (>20). †Student t test P value for comparison with the AUC for the monofilament score.
tion of normal levels, termed normoalbuminuria, serves to identify those individuals with the lowest subsequent risk of diabetic nephropathy. However, the longitudinal clinical studies that are necessary for identifying a comparable marker of incipient nerve injury are insufficient. The current evidence for neuropathy is only supported by cross-sectional studies (10–13,22,23).

With the aim of finding the comparable marker of incipient nerve injury, we chose to evaluate the quantitative monofilament score. Previous work had demonstrated in cross-sectional analysis that a monofilament score of ≥7 correct responses out of 8 had high sensitivity (77%), whereas a score of ≤3 correct responses out of 8 had very high specificity (96%) for the concurrent presence of diabetic neuropathy (10). The question remained whether a single score or range of scores in between these two thresholds could represent incipient nerve injury. The current analysis was designed to answer this specific question by identifying a large group of subjects without diabetic neuropathy and to determine the operating characteristics of the monofilament score for the 4-year incidence of neuropathy. Because a score of ≤3 correct responses out of 8, associated with presence of neuropathy in the cross-sectional study, was uncommon in the current study (18% of participants), we can interpret the results of both the cross-sectional and longitudinal study together: When the monofilament examination is applied as a screening test, a score of ≤3 correct responses out of 8 indicates a very high likelihood of current diabetic neuropathy. A score of 4–5 correct responses out of 8 indicates incipient neuropathy. Subjects with such scores are unlikely to have neuropathy at the time of examination but, rather, have a high 4-year risk of its incidence. In clinical practice, knowledge of this risk might help motivate attainment of glycemic targets as glycemic control is the only known disease-modifying intervention for DSP. For research into disease-modifying therapies, subjects with such scores could be accrued as high-risk subjects for inclusion in clinical trials. The remaining scores of 6–8 correct responses out of 8 indicate both a lack of neuropathy and the lowest 4-year risk of its incidence.

The theoretical comparisons between the monofilament examination and assessment of urinary albumin excretion extend to the performance characteristics of these two tests. The low positive predictive value of the monofilament score threshold of ≤5 correct responses out of 8 (the upper threshold for incipient nerve injury) is in fact very consistent with the low positive predictive value for microalbuminuria (24). Despite this limitation, assessment of microalbuminuria remains a standard of diabetes care, owing to the benefit of its sensitivity. Similarly, we view the benefit of the monofilament examination as a screening test for diabetic neuropathy to be attributable to its sensitivity.

Although unique as a longitudinal study of predictive validity in diabetic neuropathy, there are potential limitations to the interpretation of the results of this study. First, the study group included a mixed cohort of type 1 and type 2 diabetic subjects, which makes an assumption that diabetic neuropathy and its clinical assessment are consistent between diabetes types. Second, the interval of time between baseline and final evaluation of the participants in this study was variable, but we were not able to detect an influence of follow-up time on the likelihood of incident diabetic neuropathy. Third, we explored our hypothesis in a derivation set without access to a validation set. To address this issue of certainty, we performed a bootstrap analysis. Finally, the reference standard definition of diabetic sensorimotor polyneuropathy remains challenging as it combines clinical and electrophysiological criteria that are not consistently aligned in individual subjects. To overcome this feature of the definition as much as possible, we used the most up-to-date definition of neuropathy (15).

Knowledge of the monofilament score permits general risk stratification of patients for future incident neuropathy. Our findings demonstrate that the monofilament examination, a valid and clinically feasible biomarker for diabetic neuropathy in cross-sectional study, also has sufficiently valid operating characteristics as a marker of incipient nerve injury in longitudinal study. Thus, the quantitative monofilament score can be used to identify those at the lowest and highest 4-year risk of diabetic neuropathy incidence. In this capacity it is aligned with other clinical tests for diabetes complications and is limited by suboptimal specificity. To further refine risk prediction of diabetic neuropathy in clinical practice, evaluation of future novel biomarkers of diabetic neuropathy must aim to report the results of longitudinal evaluation for predictive validity and compare these to the operating characteristics reported here for the monofilament examination.

Acknowledgments—This research was supported by Canadian Diabetes Association grant AR-2-06-2056-BP. B.A.P. is a Canadian Diabetes Association Scholar and was supported by the Banting and Best Diabetes Center.

No potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in poster form at the 69th annual meeting of the American Diabetes Association, New Orleans, Louisiana, 5–9 June 2009.

We acknowledge the assistance of Alessandro Doria and Monika Niewczas with the statistical tests comparing receiver operating characteristic area under the curve and of Tim Shin for aspects of manuscript preparation. We are also indebted to the dedicated work of Rachel Kaufman for assistance with data management and manuscript preparation.

References
1. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Mannes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH, EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352:341–350.
2. Dyck JB, Dyck PJ. Diabetic neuropathy: In Diabetic Neuropathy. Dyck PJ, Thomas PK, Eds. Philadelphia, WB Saunders, 1999, p. 244–248.
3. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28:956–962.
4. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian J. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790–1795.
5. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995;38:869–880.
6. Harris SB, Worrall G, Macaulay AC, Norton P, Webster-Bogaert S, Donner A, Murray A, Stewart M. Diabetes Management in Canada: baseline results of the group practice diabetes management study. Can J Diabetes 2006;30:131–137.
7. Olmos PR, Cataland S, O’Doriso TM, Casey CA, Smed WL, Simon SR. The Semmes-Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Am J Med Sci 1995;309:76–82.
8. Smieja M, Hunt DL, Edelman D, Eichells E, Cornuz J, Simel DL. Clinical examination for the detection of protective sensa-
tion in the feet of diabetic patients. International Cooperative Group for Clinical Examination Research. J Gen Intern Med 1999;14:418–424
9. Pham H, Armstrong DG, Harvey C, Har- kless LB, Giurini JM, Veves A. Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 2000;23: 606–611
10. Perkins BA, Olaleye D, Zinman B, Bril V. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001;24:250–256
11. Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med 2003;20:368–374
12. Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetic Res Clin Pract 2001;54:115–128
13. Bril V, Perkins B. Neuropathy. Canadian Diabetes Association Clinical Guidelines Expert Committee. Can J Diabetes 2008; 32(Suppl. 1):S140–142
14. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002;25: 2048–2052
15. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, Cohen JA, Fisher MA, Howard JF, Kinse1 LA, Latov N, Lewis RA, Low PA, Sumner AJ. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64:199–207
16. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27:1458–1486
17. Perkins BA, Ngo M, Bril V. Symmetry of nerve conduction studies in different stages of diabetic polyneuropathy. Muscle Nerve 2002;25:212–217
18. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29
19. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561–577
20. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157–172, discussion 207–212
21. Williams ME. Diabetic nephropathy: the proteinuria hypothesis. Am J Nephrol 2005;25:77–94
22. Rith-Najarian SJ, Stolusky T, Gohdes DM. Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria. Diabetes Care 1992;15: 1386–1389
23. Thomson MP, Potter J, Finch PM, Paisey RB. Threshold for detection of diabetic peripheral sensory neuropathy using a range of research grade monofilaments in persons with type 2 diabetes mellitus. J Foot Ankle Res 2008;1:9
24. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348: 2285–2293

Predictive validity of monofilament examination